The application of molecular biomarkers provides new insights for ccRCC's treatment and prognostic prediction, such as proliferation markers (Ki-67 and PTEN) and hypoxia-inducible factor members (vascular endothelial growth factor) (9, 27). Here, PTEN is linked to nonpapillary renal cell carcinoma.